Previous close | 51.07 |
Open | 51.13 |
Bid | 51.30 x 1200 |
Ask | 52.75 x 1200 |
Day's range | 50.91 - 51.54 |
52-week range | 34.98 - 54.17 |
Volume | |
Avg. volume | 9,403,941 |
Market cap | 73.725B |
Beta (5Y monthly) | 0.80 |
PE ratio (TTM) | 86.92 |
EPS (TTM) | 0.59 |
Earnings date | 25 Jul 2023 - 31 Jul 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 54.16 |
Catalent's (CTLT) expansion of its OneBio Suite across multiple biologic therapies is expected to aid customers in leveraging its end-to-end capabilities in these areas.
Inari Medical's (NARI) latest launches are expected to serve a wider patient pool by improving treatment options.
Investors continue to be optimistic about Intuitive Surgical (ISRG) owing to its strength in robotics.
Masimo's (MASI) Radius VSM is expected to equip any hospital bed with comprehensive monitoring and offer more personalized care without additional bedside equipment.
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2024.
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and a solid foothold in the broader MedTech space.
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But the truth is...
PacBio's (PACB) product development activities raise optimism about the stock.
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both segments.
Investors remain optimistic about DaVita (DVA) due to the strength of its DaVita Kidney Care.
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
Veeva Systems (VEEV) expands its partnership with Lotus Clinical to accelerate clinical trials.
Boston Scientific (BSX) gains from strong improvement in organic sales, indicating a solid rebound in the legacy business.
Here is how Augmedix, Inc. (AUGX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.
Boston Scientific's (NYSE:BSX) stock is up by 9.1% over the past three months. However, the company's financials look a...
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Veeva Systems' (VEEV) Vault Quality Suite applications are expected to aid the CDMO to modernize its operations and streamline its quality processes globally.
Strong growth in the Cardiovascular, Medical Surgical, and Neuroscience portfolios, and in Diabetes markets drove Medtronic (MDT) Q4 revenues.
Masimo's (MASI) latest expansion to its HEOS platform will likely revolutionize health and wellness tracking by allowing connected care as consumers become tetherless and smartphone-less.
Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.
Investors are optimistic about Accuray's (ARAY) solid product portfolio.
Veeva Systems' (VEEV) latest collaboration is expected to advance the patient experience in clinical trials.
Key Insights Using the 2 Stage Free Cash Flow to Equity, Boston Scientific fair value estimate is US$41.38 Current...